Frankfurt Oder

Researchers are collecting data in a registry study for adults diagnosed with acute myeloid leukemia AML, including newly diagnosed and relapsed cases. The study aims to gather important information about the diseases epidemiology, such as patient age and prognostic factors, and to compare incidence and age distribution with population tumor registry data. It also evaluates key clinical outcomes like relapse-free survival, time to relapse, cumulative incidence of relapse, and overall survival. This observational study does not involve treatment assignment but documents treatment strategies used by patients. Data is gathered over a 10-year period to thoroughly monitor outcomes and disease patterns. The registry also collects information on complete remission rates, treatment-related mortality, therapy-associated morbidity, and quality of therapy and diagnosis. Additionally, the study seeks to validate known prognostic factors and explore new ones while describing new therapies and supportive care measures. Participants are adults aged 18 years and older diagnosed with AML according to WHO criteria, including acute promyelocytic leukemia. The study involves long-term follow-up with yearly assessments over 10 years. Researchers will evaluate epidemiological parameters and important survival outcomes. Since this is an observational registry, participants continue with their usual care while data is collected. The study is sponsored by Technische Universitt Dresden and involves multiple sites in Germany.

The German Dementia Registry DEMREG is a large-scale national study focused on collecting real-world data from patients diagnosed with Subjective Cognitive Decline SCD, Mild Cognitive Impairment MCI, and early dementia of various types in Germany. The study aims to follow patients over time to better understand the natural progression of dementia and differences between types such as Alzheimers and other dementias. It provides a clinical platform for research that aligns with current diagnostic and treatment guidelines. This is an observational registry study where no treatments are given as part of the research. Instead, patients usual care and medications are documented. Data are collected through patient visits using questionnaires and tests related to early dementia. The registry collects biomarker data, including cerebrospinal fluid and imaging markers, and follows patients annually for as long as possible to track changes over time. Participants will have baseline and yearly follow-up visits where clinical data, biomarker results, and questionnaire information are gathered. The study monitors the natural course of dementia and changes in biomarkers, aiming to inform future diagnostic criteria and treatment approaches. Participation involves consenting patients and optionally family members who are involved in the patients care. The registry is ongoing with long-term follow-up planned.

Researchers are studying patients with metastatic castration-resistant prostate cancer mCRPC who are starting treatment with lutetium 177Lu vipivotide tetraxetan. This observational study aims to describe routine clinical practice and the impact of this treatment on patients health-related quality of life HRQoL at various stages, including before treatment, during treatment, and after disease progression. Patients will receive lutetium 177Lu vipivotide tetraxetan in treatment cycles lasting about 6 weeks each, with up to 6 cycles total as guided by local treatment labels. Data collection points include before treatment begins if eligible, the first administration date, throughout treatment, at the end of treatment EoT, and during follow-up up to one year after the last treatment. During the study, patients will complete questionnaires to assess quality of life and pain levels, and clinical data such as progression and survival will be recorded. Researchers will monitor changes in scores from baseline through one year after treatment ends. Follow-up data collection depends on availability and may continue for up to a year post-treatment. The study is sponsored by Novartis Pharmaceuticals and focuses on real-world patient experiences.

Researchers are observing adults with Chronic Lymphocytic Leukemia CLL who are receiving the drug venetoclax, either alone or combined with other medications such as rituximab, obinutuzumab, ibrutinib, or acalabrutinib. The study aims to understand how these treatments work in real-life settings, focusing on the effectiveness, costs related to health economics, and outcomes reported by the patients themselves. Participants receive venetoclax as prescribed by their doctors following local medical guidelines. They may receive it alone or alongside one of the other drugs mentioned. This study does not assign treatments but observes patients as they undergo therapy according to routine clinical practice across several countries. During the study, participants are monitored for their response to treatment, with the main focus on the best overall response rate within 12 months. Researchers collect data on health outcomes, costs, and patient experiences to better understand the impact of these therapies. The study spans several years, allowing long-term observation of treatment effects and outcomes.